Doctor’s Passport

Find your next topic

Explore the current textbook

Available drafts · Clinical review pending
Membership
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
Rapid

Atheroembolic renal disease

Essential points for quick revision.

Saved on this device
!
Multisystem embolisation

Rapid renal deterioration with bowel ischaemia, neurological deficit, retinal emboli, gangrene or uncontrolled hypertension may signal extensive cholesterol embolisation.

Action: Admit, assess organ perfusion urgently, involve nephrology and the relevant vascular or organ team, and treat life-threatening complications while avoiding unnecessary further arterial instrumentation.

Synopsis

Recognise delayed cholesterol crystal embolisation after vascular manipulation, distinguish it from contrast-associated AKI and vasculitis, and provide supportive renal and cardiovascular care without claiming an unproven disease-specific drug.

  • Think AERD when AKI appears days to weeks after aortic or arterial instrumentation and is accompanied by livedo, blue toes or retinal cholesterol emboli despite preserved distal pulses.
  • The renal trajectory is often delayed and staircase-like, unlike the earlier creatinine rise typical of uncomplicated contrast-associated AKI.
  • Treatment is supportive—manage volume, electrolytes, blood pressure and dialysis indications, avoid unnecessary further arterial manipulation, and use atorvastatin for cardiovascular prevention rather than crystal removal. Do not give corticosteroids routinely or reflexively stop essential antithrombotics; evidence for steroids is unconfirmed and antithrombotic indications require specialist reconciliation. Eosinophilia, low complement and inflammatory markers remain supportive, not diagnostic.

Key red flags

Oliguria, refractory hyperkalaemia, acidosis, pulmonary oedema or uraemic complications require immediate nephrology and critical-care discussion of renal replacement therapy.

Severe abdominal pain, gastrointestinal bleeding or peritonism may represent mesenteric cholesterol embolisation and requires urgent imaging and surgical assessment.

New focal neurology, retinal ischaemia or rapidly progressive gangrene indicates a systemic embolic shower rather than isolated kidney injury.

Fever, a murmur and positive blood cultures raise infective endocarditis with septic emboli, which must be distinguished before immunosuppression.

Purpura with glomerular urine sediment, major proteinuria or disease-specific serology should prompt assessment for vasculitis or glomerulonephritis.

Multiorgan disease

Retinal plaques, neurological events, myalgia, abdominal pain or gastrointestinal bleeding alongside AKI strengthen the diagnosis and indicate a larger embolic burden.

Severe renal presentation

Oliguria, pulmonary oedema, resistant hypertension, hyperkalaemia, acidosis or uraemia signals advanced injury and requires urgent nephrology support.

Investigation priorities

01
Serial creatinine, urine output and electrolytesFirst step

Define timing, severity and renal-support needs rather than relying on one creatinine.

Management branches

Worked caseAKI after coronary angiography

Creatinine rises ten days after angiography and the patient has livedo, blue toes and preserved pedal pulses.

  1. Plot creatinine and procedures over time, assess urine output and emergencies, and examine skin, pulses, retina, abdomen and neurology for a systemic shower.
  2. Compare alternatives: early contrast-associated AKI, pre-renal injury, renal infarction, vasculitis and infective emboli; send urine, blood count, complement, inflammatory markers and cultures when infection is plausible.

Key medicines

AtorvastatinFor a person with CKD, offer atorvastatin 20 mg orally once daily for primary or secondary cardiovascular prevention; if the lipid target is unmet, increase when eGFR is at least 30 mL/min/1.73 m², but agree higher doses with a renal specialist when eGFR is below 30. Outside CKD, NICE offers 80 mg once daily for secondary prevention unless modification criteria apply.The product SmPC requires no pharmacokinetic renal adjustment, but NICE still supplies a CKD-specific starting and escalation regimen. Check liver enzymes, CYP3A4 interactions and muscle symptoms; active liver disease and pregnancy are contraindications. Continue long term while indicated and tolerated.
Open full textbook Answer 2 questions
Sources and review status5 sources · checked 13 Sept 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 13 Sept 2026; clinical approval remains outstanding.

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom